Wolk A, Mantzoros C S, Andersson S O, Bergström R, Signorello L B, Lagiou P, Adami H O, Trichopoulos D
Department of Medical Epidemiology, Karolinska Institute, Stockholm, Sweden.
J Natl Cancer Inst. 1998 Jun 17;90(12):911-5. doi: 10.1093/jnci/90.12.911.
Recent epidemiologic investigations have suggested an association between increased blood levels of insulin-like growth factor 1 (IGF-1) and increased risk of prostate cancer. Our goal was to determine whether an association exists between serum levels of IGF-1 and one of its binding proteins, insulin-like growth factor-binding protein 3 (IGFBP-3), and prostate cancer risk.
An immunoradiometric assay was used to quantify IGF-1 levels and IGFBP-3 levels in serum samples as part of a population-based, case-control study in Sweden. The study population comprised 210 patients with newly diagnosed, untreated prostate cancer and 224 frequency-matched control subjects. Data were analyzed by use of unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Reported P values are two-sided.
The mean serum IGF-1 level for case patients (158.4 ng/mL) was significantly higher than that for control subjects (147.4 ng/mL) (P = .02); corresponding mean serum IGFBP-3 levels were not significantly different between case patients (2668 ng/mL) and control subjects (2518 ng/mL) (P =.09). We found a moderately strong and statistically significant (P = .04) positive association between serum levels of IGF-1 levels and risk of prostate cancer (OR = 1.51; 95% CI = 1.0-2.26 per 100 ng/mL increment); the association was particularly strong for men younger than 70 years of age (OR = 2.93; 95% CI = 1.43-5.97). No association was found between serum IGF-1 levels and disease stage. Serum IGFBP-3 levels were not significantly associated with increased risk of disease, and adjustment for IGFBP-3 had little effect on the association between IGF-1 levels and risk of prostate cancer.
Elevated serum IGF-1 levels may be an important predictor of risk for prostate cancer. However, our results do not support an important role for serum IGFBP-3 as a predictor of risk for this disease.
近期的流行病学调查表明，血液中胰岛素样生长因子1（IGF-1）水平升高与前列腺癌风险增加之间存在关联。我们的目标是确定血清IGF-1水平及其结合蛋白之一胰岛素样生长因子结合蛋白3（IGFBP-3）与前列腺癌风险之间是否存在关联。
作为瑞典一项基于人群的病例对照研究的一部分，采用免疫放射分析法定量血清样本中的IGF-1水平和IGFBP-3水平。研究人群包括210例新诊断的未经治疗的前列腺癌患者和224例频率匹配的对照对象。使用无条件逻辑回归分析数据，以计算比值比（OR）和95%置信区间（CI）。报告的P值为双侧。
病例患者的血清IGF-1平均水平（158.4 ng/mL）显著高于对照对象（147.4 ng/mL）（P = 0.02）；病例患者（2668 ng/mL）和对照对象（2518 ng/mL）的相应血清IGFBP-3平均水平无显著差异（P = 0.09）。我们发现血清IGF-1水平与前列腺癌风险之间存在中等强度且具有统计学意义（P = 0.04）的正相关（每增加100 ng/mL，OR = 1.51；95% CI = 1.0 - 2.26）；对于70岁以下的男性，这种关联尤为强烈（OR = 2.93；95% CI = 1.43 - 5.97）。未发现血清IGF-1水平与疾病分期之间存在关联。血清IGFBP-3水平与疾病风险增加无显著关联，对IGFBP-3进行校正对IGF-1水平与前列腺癌风险之间的关联影响不大。
血清IGF-1水平升高可能是前列腺癌风险的重要预测指标。然而，我们的结果不支持血清IGFBP-3作为该疾病风险预测指标的重要作用。
